New analysis highlights the cardiorenal benefits of SGLT2 inhibitors

KEY POINT

Use of select sodium–glucose cotransporter-2 inhibitors (SGLT2i) resulted in significant reductions in the risk of major cardiovascular (CV) events in patients with diabetes and established CV disease but not in those with only CV risk factors. However, use of these agents resulted in significant reductions in hospitalizations for heart failure and progression of renal disease in patients with or without existing atherosclerotic disease, according to results of a systematic review and meta-analysis published in the Lancet.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.